PR Newswire BiotechOriginal article
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
TAVST01Positive
AI Analysis
Summary
Tikva Allocell closed $8 million Series A financing to advance TAVST01, an engineered EBV-specific CAR-T therapy for B7-H3-positive solid tumors. The funding will support IND-enabling activities with a planned year-end IND submission.
Importance:6/10
Sentiment:
0.70
Series A fundingCAR-T therapyIND submissionsolid tumorsoff-the-shelf therapy
Related Companies
Read the original article
Published by PR Newswire Biotech on July 22, 2026 11:03 AM